
Supriya Shore

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4998622/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Interhospital variability in health care–associated infections and payments after durable ventricular assist device implant among Medicare beneficiaries. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1561-1568.	0.8	10
2	A challenge to equity in transplantation: Increased center-level variation in short-term mechanical circulatory support use in the context of the updated U.S. heart transplant allocation policy. Journal of Heart and Lung Transplantation, 2022, 41, 95-103.	0.6	16
3	Generalizability of Trial Data to Real-World Practice: An Analysis of The Society of Thoracic Surgeons Intermacs Database. Annals of Thoracic Surgery, 2022, 114, 1307-1317.	1.3	4
4	Non-patient factors associated with infections in LVAD recipients: A scoping review. Journal of Heart and Lung Transplantation, 2022, 41, 1-16.	0.6	8
5	Patient factors associated with left ventricular assist device infections: A scoping review. Journal of Heart and Lung Transplantation, 2022, 41, 425-433.	0.6	10
6	Correction: Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2022, 11, e39663.	1.0	0
7	Current status and barriers in pulmonary hypertension care delivery in India: A qualitative analysis. Pulmonary Circulation, 2022, 12, .	1.7	1
8	Assessment of Mortality Among Durable Left Ventricular Assist Device Recipients Ineligible for Clinical Trials. JAMA Network Open, 2021, 4, e2032865.	5.9	11
9	Temporary Mechanical Circulatory Support as a Bridge to Heart Transplant or Durable Left Ventricular Assist Device. Interventional Cardiology Clinics, 2021, 10, 235-249.	0.4	3
10	Characteristics and Outcomes of COVID-19 in Patients on Left Ventricular Assist Device Support. Circulation: Heart Failure, 2021, 14, e007957.	3.9	24
11	Guiding Sisyphus's Boulder to the Top. Circulation: Cardiovascular Quality and Outcomes, 2021, 14, e008465.	2.2	0
12	Changes in the United States Adult Heart Allocation Policy. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e005795.	2.2	43
13	Annals for Hospitalists Inpatient Notes - Novel and Advanced Therapies for Heart Failure—What a Hospitalist Needs to Know. Annals of Internal Medicine, 2020, 173, HO2-HO3.	3.9	0
14	The effect of transfusion of blood products on ventricular assist device support outcomes. ESC Heart Failure, 2020, 7, 3573-3581.	3.1	11
15	Heart Failure and Shared Decision-Making: Patients Open to Medication-Related Cost Discussions. Circulation: Heart Failure, 2020, 13, e007094.	3.9	22
16	Understanding and Addressing Variation in Health Care–Associated Infections After Durable Ventricular Assist Device Therapy: Protocol for a Mixed Methods Study. JMIR Research Protocols, 2020, 9, e14701.	1.0	5
17	Discussing Outâ€ofâ€Pocket Costs With Patients: Shared Decision Making for Sacubitrilâ€Valsartan in Heart Failure. Journal of the American Heart Association, 2019, 8, e010635.	3.7	37
18	Trends in Consent for Clinical Trials in Cardiovascular Disease. Journal of the American Heart Association, 2016, 5, .	3.7	8

SUPRIYA SHORE

#	Article	IF	CITATIONS
19	Health Status Outcomes in Patients With Acute Myocardial Infarction After Rehospitalization. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 777-784.	2.2	7
20	Guidelineâ€Directed Medication Use in Patients With Heart Failure With Reduced Ejection Fraction in India: American College of Cardiology's <scp>PINNACLE</scp> India Quality Improvement Program. Clinical Cardiology, 2016, 39, 145-149.	1.8	22
21	Clinical Relevance of Rehospitalizations for Unstable Angina and Unplanned Revascularization Following Acute Myocardial Infarction. Journal of the American Heart Association, 2016, 5, .	3.7	1
22	Improving diabetes diagnosis and management in myocardial infarction patients: overcoming clinical inertia. Expert Review of Endocrinology and Metabolism, 2015, 10, 127-129.	2.4	0
23	Sudden Infant Death Syndrome and Residential Altitude. Pediatrics, 2015, 135, e1442-e1449.	2.1	14
24	Site-Level Variation in and Practices Associated With Dabigatran Adherence. JAMA - Journal of the American Medical Association, 2015, 313, 1443.	7.4	124
25	Longitudinal persistence with secondary prevention therapies relative to patient risk after myocardial infarction. Heart, 2015, 101, 800-807.	2.9	52
26	Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure Patients Stratified by Etiologies of Cardiomyopathy. JACC: Heart Failure, 2015, 3, 906-916.	4.1	54
27	Response to Comment on Shore et al. Association Between Hyperglycemia at Admission During Hospitalization for Acute Myocardial Infarction and Subsequent Diabetes: Insights From the Veterans Administration Cardiac Care Follow-up Clinical Study. Diabetes Care 2014;37:409–418. Diabetes Care, 2014. 37. e168-e168.	8.6	1
28	Cardiovascular highlights from non-cardiology journals. Heart, 2014, 100, 348-348.	2.9	0
29	Cardiovascular highlights from non-cardiology journals. Heart, 2014, 100, 892-892.	2.9	0
30	Association Between Hyperglycemia at Admission During Hospitalization for Acute Myocardial Infarction and Subsequent Diabetes: Insights From the Veterans Administration Cardiac Care Follow-up Clinical Study. Diabetes Care, 2014, 37, 409-418.	8.6	29
31	Adherence to dabigatran therapy and longitudinal patient outcomes: Insights from the Veterans Health Administration. American Heart Journal, 2014, 167, 810-817.	2.7	207
32	Gap between clinical guidelines and practice: The case of aldosterone-antagonists in patients with myocardial infarction. International Journal of Cardiology, 2014, 172, e151-e153.	1.7	3
33	Invasive coronary procedure use and outcomes among veterans with posttraumatic stress disorder: Insights from the Veterans Affairs Clinical Assessment, Reporting, and Tracking Program. American Heart Journal, 2014, 168, 381-390.e6.	2.7	7
34	Carvedilol or Sustained-Release Metoprolol for Congestive Heart Failure: A Comparative Effectiveness Analysis. Journal of Cardiac Failure, 2012, 18, 919-924.	1.7	9
35	214 Improved Survival with Sustained Release Metoprolol When Compared to Carvedilol in Patients with Ischemic Heart Failure: A Comparative Effectiveness Analysis. Journal of Heart and Lung Transplantation, 2011, 30, S78.	0.6	0
36	215 Higher Doses of Spirinolactone Are Associated with Lower Survival in Patients with Congestive Heart Failure. Journal of Heart and Lung Transplantation, 2011, 30, S78.	0.6	0

#	Article	IF	CITATIONS
37	499 Improved Survival with Statin Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction. Journal of Heart and Lung Transplantation, 2011, 30, S169.	0.6	Ο
38	504 Improved Survival with Pioglitazone in Patients with Diabetes Mellitus, Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction: A Comparative Effectiveness Analysis. Journal of Heart and Lung Transplantation, 2011, 30, S171.	0.6	0
39	678 Dose-Dependent Improvement in Survival with ACE Inhibitor Use in Patients with Pulmonary Arterial Hypertension and Heart Failure with Normal Ejection Fraction. Journal of Heart and Lung Transplantation, 2011, 30, S226.	0.6	Ο